Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616045 | 1.00 | MEN1 (0.38) | MEN1KMT2AEGFRNPC1RAB9A | |
| SCHEMBL13616416 | 0.95 | MEN1 (0.37) | MEN1KMT2AEGFRNPC1RAB9A | |
| SCHEMBL13616414 | 0.95 | MEN1 (0.37) | MEN1KMT2AEGFRNPC1RAB9A | |
| SCHEMBL13616041 | 0.95 | MEN1 (0.37) | MEN1KMT2AEGFRNPC1RAB9A | |
| SCHEMBL13616417 | 0.92 | MEN1 (0.39) | MEN1KMT2ANPC1RAB9AGFER | |
| SCHEMBL13616200 | 0.92 | MEN1 (0.39) | MEN1KMT2ANPC1RAB9AGFER | |
| SCHEMBL3422794 | 0.92 | MEN1 (0.39) | MEN1KMT2ANPC1RAB9AGFER | |
| SCHEMBL3422797 | 0.92 | MEN1 (0.39) | MEN1KMT2ANPC1RAB9AGFER | |
| SCHEMBL13616188 | 0.90 | MEN1 (0.38) | MEN1KMT2ANPC1RAB9AGFER | |
| SCHEMBL13616435 | 0.90 | MEN1 (0.38) | MEN1KMT2ANPC1RAB9AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | MEN1 4697/4885KMT2A 1752/4885EGFR 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.